East Bay gene editing company snags Gilead deal worth up to $3.2 billion
February 22, 2018 at 09:16 AM EST
With the biotech industry's focus on the CRISPR, the Peninsula's Gilead goes local to focus on another gene-editing technology, underscoring a year-long effort by its new East Bay partner.
